Tyra Biosciences, Inc. $TYRA Shares Sold by Eversept Partners LP

Eversept Partners LP cut its stake in Tyra Biosciences, Inc. (NASDAQ:TYRA) by 90.3% during the 1st quarter, Holdings Channel.com reports. The fund owned 27,055 shares of the company’s stock after selling 251,509 shares during the period. Eversept Partners LP’s holdings in Tyra Biosciences were worth $1,036,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the stock. Millennium Management LLC increased its position in Tyra Biosciences by 28.2% during the first quarter. Millennium Management LLC now owns 404,165 shares of the company’s stock worth $3,759,000 after purchasing an additional 89,024 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Tyra Biosciences by 21.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 78,006 shares of the company’s stock valued at $725,000 after purchasing an additional 13,896 shares during the last quarter. Woodline Partners LP acquired a new position in shares of Tyra Biosciences in the 1st quarter valued at $931,000. Jane Street Group LLC purchased a new stake in shares of Tyra Biosciences during the 1st quarter valued at $324,000. Finally, Geode Capital Management LLC grew its stake in shares of Tyra Biosciences by 9.8% during the 2nd quarter. Geode Capital Management LLC now owns 567,126 shares of the company’s stock valued at $5,428,000 after buying an additional 50,836 shares during the period. 84.14% of the stock is currently owned by hedge funds and other institutional investors.

Tyra Biosciences Stock Up 1.4%

TYRA opened at $31.06 on Tuesday. Tyra Biosciences, Inc. has a 52-week low of $9.96 and a 52-week high of $40.65. The company has a 50 day moving average of $30.59 and a two-hundred day moving average of $32.63. The company has a market cap of $1.85 billion, a P/E ratio of -14.25 and a beta of 0.76.

Tyra Biosciences (NASDAQ:TYRA) last issued its earnings results on Wednesday, May 13th. The company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.04). Research analysts anticipate that Tyra Biosciences, Inc. will post -2.68 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on TYRA shares. JonesTrading began coverage on Tyra Biosciences in a research report on Wednesday, June 17th. They issued a “buy” rating and a $56.00 target price on the stock. Canaccord Genuity Group started coverage on Tyra Biosciences in a research report on Monday, April 6th. They set a “buy” rating and a $50.00 price target for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Tyra Biosciences in a research note on Friday, July 17th. HC Wainwright restated a “buy” rating and set a $45.00 price target on shares of Tyra Biosciences in a research note on Thursday, May 14th. Finally, Guggenheim initiated coverage on Tyra Biosciences in a report on Tuesday, April 14th. They issued a “buy” rating and a $54.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $47.00.

Tyra Biosciences Profile

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.